 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CLONAZEPAM increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does CLONAZEPAM increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes CLONAZEPAM increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CLONAZEPAM increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does CLONAZEPAM increase the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"clonazepam"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: CLONAZEPAM: adverse_reactions: While these findings are noteworthy, Hamilton Depression Rating Scale [0m[1;31m([0m[31mHAM-D[0m[1;31m)[0m[31m data collected in these trials revealed a larger decline in HAM-D scores in the [0m
[31mclonazepam group than the placebo group suggesting that clonazepam-treated patients were not experiencing a worsening or emergence of clinical depression. Other Adverse Events Observed During the [0m
[31mPremarketing Evaluation of Clonazepam Tablets in Panic Disorder: Following is a list of modified CIGY terms that reflect treatment-emergent adverse events reported by patients treated with clonazepam [0m
[31mtablets at multiple doses during clinical trials. All reported events are included except those already listed in Table [0m[1;31m3[0m[31m or elsewhere in labeling, those events for which a drug cause was remote, [0m
[31mthose event terms which were so general as to be uninformative, and events reported only once and which did not have a substantial probability of being acutely life-threatening. CLONAZEPAM: [0m
[31madverse_reactions: It is important to emphasize that, although the events occurred during treatment with clonazepam tablets, they were not necessarily caused by it. Events are further categorized by [0m
[31mbody system and listed in order of decreasing frequency. These adverse events were reported infrequently, which is defined as occurring in [0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m to [0m[1;31m1[0m[31m/[0m[1;31m1000[0m[31m patients. CLONAZEPAM: adverse_reactions: Body[0m
[31mas a Whole: weight increase, accident, weight decrease, wound, edema, fever, shivering, abrasions, ankle edema, edema foot, edema periorbital, injury, malaise, pain, cellulitis, inflammation localized[0m
[31mCardiovascular Disorders: chest pain, hypotension postural Central and Peripheral Nervous System Disorders: migraine, paresthesia, drunkenness, feeling of enuresis, paresis, tremor, burning skin, [0m
[31mfalling, head fullness, hoarseness, hyperactivity, hypoesthesia, tongue thick, twitching Gastrointestinal System Disorders: abdominal discomfort, gastrointestinal inflammation, stomach upset, [0m
[31mtoothache, flatulence, pyrosis, saliva increased, tooth disorder, bowel movements frequent, pain pelvic, dyspepsia, hemorrhoids Hearing and Vestibular Disorders: vertigo, otitis, earache, motion [0m
[31msickness Heart Rate and Rhythm Disorders: palpitation Metabolic and Nutritional Disorders: thirst CLONAZEPAM: adverse_reactions: , gout Musculoskeletal System Disorders: back pain, fracture traumatic,[0m
[31msprains and strains, pain leg, pain nape, cramps muscle, cramps leg, pain ankle, pain shoulder, tendinitis, arthralgia, hypertonia, lumbago, pain feet, pain jaw, pain knee, swelling knee Platelet, [0m
[31mBleeding and Clotting Disorders: bleeding dermal Psychiatric Disorders: insomnia, organic disinhibition, anxiety, depersonalization, dreaming excessive, libido loss, appetite increased, libido [0m
[31mincreased, reactions decreased, aggression, apathy, disturbance in attention, excitement, anger, hunger abnormal, illusion, nightmares, sleep disorder, suicide ideation, yawning Reproductive [0m
[31mDisorders, Female: breast pain, menstrual irregularity Reproductive Disorders, Male: ejaculation decreased Resistance Mechanism Disorders: infection mycotic, infection viral, infection streptococcal, [0m
[31mherpes simplex infection, infectious mononucleosis, moniliasis Respir CLONAZEPAM: adverse_reactions: atory System Disorders: sneezing excessive, asthmatic attack, dyspnea, nosebleed, pneumonia, [0m
[31mpleurisy Skin and Appendages Disorders: acne flare, alopecia, xeroderma, dermatitis contact, flushing, pruritus, pustular reaction, skin burns, skin disorder Special Senses Other, Disorders: taste [0m
[31mloss Urinary System Disorders: dysuria, cystitis, polyuria, urinary incontinence, bladder dysfunction, urinary retention, urinary tract bleeding, urine discoloration Vascular [0m[1;31m([0m[31mExtracardiac[0m[1;31m)[0m[31m Disorders:[0m
[31mthrombophlebitis leg Vision Disorders: eye irritation, visual disturbance, diplopia, eye twitching, styes, visual field defect, xerophthalmia         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: adverse_reactions: â€  Indicates that the p-value for the dose-trend test [0m[1;31m([0m[31mCochran-Mantel-Haenszel[0m[1;31m)[0m[31m for adverse event incidence was â‰¤ [0m[1;31m0.10[0m[31m. â€¡ Denominators for events in [0m
[31mgender-specific systems are: n = [0m[1;31m240[0m[31m [0m[1;31m([0m[31mclonazepam[0m[1;31m)[0m[31m, [0m[1;31m102[0m[31m [0m[1;31m([0m[31mplacebo[0m[1;31m)[0m[31m for male, and [0m[1;31m334[0m[31m [0m[1;31m([0m[31mclonazepam[0m[1;31m)[0m[31m, [0m[1;31m192[0m[31m [0m[1;31m([0m[31mplacebo[0m[1;31m)[0m[31m for female. CLONAZEPAM: adverse_reactions: Clonazepam Maximum Daily Dose Adverse Event by[0m
[31mBody System < [0m[1;31m1[0m[31m mg n = [0m[1;31m96[0m[31m % [0m[1;31m1[0m[31m - < [0m[1;31m2[0m[31m mg n = [0m[1;31m129[0m[31m % [0m[1;31m2[0m[31m - < [0m[1;31m3[0m[31m mg n = [0m[1;31m113[0m[31m % â‰¥ [0m[1;31m3[0m[31m mg n = [0m[1;31m235[0m[31m % All Clonazepam Tablets Groups N = [0m[1;31m574[0m[31m % Placebo N = [0m[1;31m294[0m[31m % Central & Peripheral Nervous System Somnolence â€  [0m[1;31m26[0m[31m [0m[1;31m35[0m[31m [0m
[1;31m50[0m[31m [0m[1;31m36[0m[31m [0m[1;31m37[0m[31m [0m[1;31m10[0m[31m Dizziness [0m[1;31m5[0m[31m [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m8[0m[31m [0m[1;31m8[0m[31m [0m[1;31m4[0m[31m Coordination Abnormal â€  [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m7[0m[31m [0m[1;31m9[0m[31m [0m[1;31m6[0m[31m [0m[1;31m0[0m[31m Ataxia â€  [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m8[0m[31m [0m[1;31m8[0m[31m [0m[1;31m5[0m[31m [0m[1;31m0[0m[31m Dysarthria â€  [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m Psychiatric Depression [0m[1;31m7[0m[31m [0m[1;31m6[0m[31m [0m[1;31m8[0m[31m [0m[1;31m8[0m[31m [0m[1;31m7[0m[31m [0m[1;31m1[0m[31m Memory Disturbance [0m[1;31m2[0m[31m [0m[1;31m5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m5[0m[31m [0m[1;31m4[0m[31m [0m[1;31m2[0m[31m Nervous [0m
[31mCLONAZEPAM: adverse_reactions: ness [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Intellectual Ability Reduced [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m Emotional Lability [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Libido Decreased [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Confusion [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Respiratory System Upper [0m
[31mRespiratory Tract Infection â€  [0m[1;31m10[0m[31m [0m[1;31m10[0m[31m [0m[1;31m7[0m[31m [0m[1;31m6[0m[31m [0m[1;31m8[0m[31m [0m[1;31m4[0m[31m Sinusitis [0m[1;31m4[0m[31m [0m[1;31m2[0m[31m [0m[1;31m8[0m[31m [0m[1;31m4[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m Rhinitis [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m Coughing [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m Pharyngitis [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m Bronchitis [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Gastrointestinal System Constipation â€  [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m5[0m[31m [0m
[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m Appetite Decreased [0m[1;31m1[0m[31m CLONAZEPAM: adverse_reactions: [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Abdominal Pain â€  [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Body as a Whole Fatigue [0m[1;31m9[0m[31m [0m[1;31m6[0m[31m [0m[1;31m7[0m[31m [0m[1;31m7[0m[31m [0m[1;31m7[0m[31m [0m[1;31m4[0m[31m Allergic Reaction [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m Musculoskeletal Myalgia [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m
[31mResistance Mechanism Disorders Influenza [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m5[0m[31m [0m[1;31m5[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m Urinary System Micturition Frequency [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Urinary Tract Infection â€  [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Vision Disorders Blurred Vision [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Reproductive [0m
[31mDisorders â€¡ Female Dysmenorrhea [0m[1;31m0[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Colpitis [0m[1;31m4[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Male Ejaculation Delayed CLONAZEPAM: adverse_reactions: [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Impotence [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Commonly Observed Adverse Events: Table [0m[1;31m4[0m[31m. [0m
[31mIncidence of Most Commonly Observed Adverse Events * in Acute Therapy in Pool of [0m[1;31m6[0m[31m- to [0m[1;31m9[0m[31m-Week Trials * Treatment-emergent events for which the incidence in the clonazepam patients was â‰¥ [0m[1;31m5[0m[31m% and at [0m
[31mleast twice that in the placebo patients.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: warnings: Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages, and [0m
[31mthose who have had longer durations of use. Acute Withdrawal Reactions The continued use of benzodiazepines, including clonazepam tablets, may lead to clinically significant physical dependence. [0m
[31mAbrupt discontinuation or rapid dosage reduction of clonazepam tablets after continued use, or administration of flumazenil [0m[1;31m([0m[31ma benzodiazepine antagonist[0m[1;31m)[0m[31m may precipitate acute withdrawal reactions, [0m
[31mwhich can be life-threatening [0m[1;31m([0m[31me.g., seizures[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee DRUG ABUSE AND DEPENDENCE: Dependence [0m[1;31m)[0m[31m . Protracted Withdrawal Syndrome In some cases, benzodiazepine users have developed a protracted withdrawal [0m
[31msyndrome with withdrawal symptoms lasting weeks to more than [0m[1;31m12[0m[31m months [0m[1;31m([0m[31msee DRUG ABUSE AND DEPENDENCE: Dependence [0m[1;31m)[0m[31m. CLONAZEPAM: warnings: Interference with Cognitive and Motor Performance: Since [0m
[31mclonazepam tablets produce CNS depression, patients receiving this drug should be cautioned against engaging in hazardous occupations requiring mental alertness, such as operating machinery or driving[0m
[31ma motor vehicle. They should also be warned about the concomitant use of alcohol or other CNS-depressant drugs during clonazepam tablets therapy [0m[1;31m([0m[31msee PRECAUTIONS: Drug Interactions and PRECAUTIONS: [0m
[31mInformation for Patients [0m[1;31m)[0m[31m. Suicidal Behavior and Ideation: Antiepileptic drugs [0m[1;31m([0m[31mAEDs[0m[1;31m)[0m[31m, including clonazepam tablets, increase the risk of suicidal thoughts or behavior in patients taking these drugs [0m
[31mfor any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood[0m
[31mor behavior. CLONAZEPAM: warnings: Pooled analyses of [0m[1;31m199[0m[31m placebo-controlled clinical trials [0m[1;31m([0m[31mmono- and adjunctive therapy[0m[1;31m)[0m[31m of [0m[1;31m11[0m[31m different AEDs showed that patients randomized to one of the AEDs had [0m
[31mapproximately twice the risk [0m[1;31m([0m[31madjusted Relative Risk [0m[1;31m1.8[0m[31m, [0m[1;31m95[0m[31m% CI:[0m[1;31m1.2[0m[31m, [0m[1;31m2.7[0m[1;31m)[0m[31m of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment [0m
[31mduration of [0m[1;31m12[0m[31m weeks, the estimated incidence rate of suicidal behavior or ideation among [0m[1;31m27[0m[31m,[0m[1;31m863[0m[31m AED-treated patients was [0m[1;31m0.43[0m[31m% compared to [0m[1;31m0.24[0m[31m% among [0m[1;31m16[0m[31m,[0m[1;31m029[0m[31m placebo-treated patients, representing an[0m
[31mincrease of approximately one case of suicidal thinking or behavior for every [0m[1;31m530[0m[31m patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated [0m
[31mpatients, but the number is too small to allow any conclusion about drug effect on suicide. CLONAZEPAM: warnings: The increased risk of suicidal thoughts or behavior with AEDs was observed as early as[0m
[31mone week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond [0m[1;31m24[0m[31m weeks, the risk of suicidal[0m
[31mthoughts or behavior beyond [0m[1;31m24[0m[31m weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs[0m
[31mof varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age [0m[1;31m([0m[1;31m5[0m[31m to [0m[1;31m100[0m[31m years[0m[1;31m)[0m[31m in the[0m
[31mclinical trials analyzed. Table [0m[1;31m1[0m[31m shows absolute and relative risk by indication for all evaluated AEDs. Table [0m[1;31m1[0m[31m. CLONAZEPAM: warnings: Risk by Indication for Antiepileptic Drugs in the Pooled [0m
[31mAnalysis Indication Placebo Drug Patients Relative Risk: Risk Difference: Patients with with Events Per Incidence of Additional Drug Events Per [0m[1;31m1000[0m[31m Patients Events in Drug Patients with [0m[1;31m1000[0m[31m Patients[0m
[31mPatients/Incidence Events per [0m[1;31m1000[0m[31m in Placebo Patients Patients Epilepsy [0m[1;31m1.0[0m[31m [0m[1;31m3.4[0m[31m [0m[1;31m3.5[0m[31m [0m[1;31m2.4[0m[31m Psychiatric [0m[1;31m5.7[0m[31m [0m[1;31m8.5[0m[31m [0m[1;31m1.5[0m[31m [0m[1;31m2.9[0m[31m Other [0m[1;31m1.0[0m[31m [0m[1;31m1.8[0m[31m [0m[1;31m1.9[0m[31m [0m[1;31m0.9[0m[31m Total [0m[1;31m2.4[0m[31m [0m[1;31m4.3[0m[31m [0m[1;31m1.8[0m[31m [0m[1;31m1.9[0m[31m The relative risk for suicidal thoughts[0m
[31mor behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric [0m
[31mindications. CLONAZEPAM: warnings: Anyone considering prescribing clonazepam tablets or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. [0m
[31mEpilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and with an increased risk of suicidal thoughts and behavior. Should suicidal [0m
[31mthoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. Patients, [0m
[31mtheir caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the [0m
[31msigns and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported [0m
[31mimmediately to healthcare providers. CLONAZEPAM: warnings: Neonatal Sedation and Withdrawal Syndrome: Use of clonazepam tablets late in pregnancy can result in sedation [0m[1;31m([0m[31mrespiratory depression, [0m
[31mlethargy, hypotonia[0m[1;31m)[0m[31m and/or withdrawal symptoms [0m[1;31m([0m[31mhyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties[0m[1;31m)[0m[31m in the neonate [0m[1;31m([0m[31msee PRECAUTIONS: Pregnancy [0m[1;31m)[0m[31m. [0m
[31mMonitor neonates exposed to clonazepam tablets during pregnancy or labor for signs of sedation and monitor neonates exposed to clonazepam tablets during pregnancy for signs of withdrawal; manage these[0m
[31mneonates accordingly.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does CLONAZEPAM increase the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"clonazepam"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does CLONAZEPAM increase the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does CLONAZEPAM increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes CLONAZEPAM increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CLONAZEPAM increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does CLONAZEPAM increase the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"clonazepam"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: CLONAZEPAM: adverse_reactions: While these findings are noteworthy, Hamilton Depression Rating Scale [0m[1;31m([0m[31mHAM-D[0m[1;31m)[0m[31m data collected in these trials revealed a larger decline in HAM-D scores in the [0m
[31mclonazepam group than the placebo group suggesting that clonazepam-treated patients were not experiencing a worsening or emergence of clinical depression. Other Adverse Events Observed During the [0m
[31mPremarketing Evaluation of Clonazepam Tablets in Panic Disorder: Following is a list of modified CIGY terms that reflect treatment-emergent adverse events reported by patients treated with clonazepam [0m
[31mtablets at multiple doses during clinical trials. All reported events are included except those already listed in Table [0m[1;31m3[0m[31m or elsewhere in labeling, those events for which a drug cause was remote, [0m
[31mthose event terms which were so general as to be uninformative, and events reported only once and which did not have a substantial probability of being acutely life-threatening. CLONAZEPAM: [0m
[31madverse_reactions: It is important to emphasize that, although the events occurred during treatment with clonazepam tablets, they were not necessarily caused by it. Events are further categorized by [0m
[31mbody system and listed in order of decreasing frequency. These adverse events were reported infrequently, which is defined as occurring in [0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m to [0m[1;31m1[0m[31m/[0m[1;31m1000[0m[31m patients. CLONAZEPAM: adverse_reactions: Body[0m
[31mas a Whole: weight increase, accident, weight decrease, wound, edema, fever, shivering, abrasions, ankle edema, edema foot, edema periorbital, injury, malaise, pain, cellulitis, inflammation localized[0m
[31mCardiovascular Disorders: chest pain, hypotension postural Central and Peripheral Nervous System Disorders: migraine, paresthesia, drunkenness, feeling of enuresis, paresis, tremor, burning skin, [0m
[31mfalling, head fullness, hoarseness, hyperactivity, hypoesthesia, tongue thick, twitching Gastrointestinal System Disorders: abdominal discomfort, gastrointestinal inflammation, stomach upset, [0m
[31mtoothache, flatulence, pyrosis, saliva increased, tooth disorder, bowel movements frequent, pain pelvic, dyspepsia, hemorrhoids Hearing and Vestibular Disorders: vertigo, otitis, earache, motion [0m
[31msickness Heart Rate and Rhythm Disorders: palpitation Metabolic and Nutritional Disorders: thirst CLONAZEPAM: adverse_reactions: , gout Musculoskeletal System Disorders: back pain, fracture traumatic,[0m
[31msprains and strains, pain leg, pain nape, cramps muscle, cramps leg, pain ankle, pain shoulder, tendinitis, arthralgia, hypertonia, lumbago, pain feet, pain jaw, pain knee, swelling knee Platelet, [0m
[31mBleeding and Clotting Disorders: bleeding dermal Psychiatric Disorders: insomnia, organic disinhibition, anxiety, depersonalization, dreaming excessive, libido loss, appetite increased, libido [0m
[31mincreased, reactions decreased, aggression, apathy, disturbance in attention, excitement, anger, hunger abnormal, illusion, nightmares, sleep disorder, suicide ideation, yawning Reproductive [0m
[31mDisorders, Female: breast pain, menstrual irregularity Reproductive Disorders, Male: ejaculation decreased Resistance Mechanism Disorders: infection mycotic, infection viral, infection streptococcal, [0m
[31mherpes simplex infection, infectious mononucleosis, moniliasis Respir CLONAZEPAM: adverse_reactions: atory System Disorders: sneezing excessive, asthmatic attack, dyspnea, nosebleed, pneumonia, [0m
[31mpleurisy Skin and Appendages Disorders: acne flare, alopecia, xeroderma, dermatitis contact, flushing, pruritus, pustular reaction, skin burns, skin disorder Special Senses Other, Disorders: taste [0m
[31mloss Urinary System Disorders: dysuria, cystitis, polyuria, urinary incontinence, bladder dysfunction, urinary retention, urinary tract bleeding, urine discoloration Vascular [0m[1;31m([0m[31mExtracardiac[0m[1;31m)[0m[31m Disorders:[0m
[31mthrombophlebitis leg Vision Disorders: eye irritation, visual disturbance, diplopia, eye twitching, styes, visual field defect, xerophthalmia         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: adverse_reactions: â€  Indicates that the p-value for the dose-trend test [0m[1;31m([0m[31mCochran-Mantel-Haenszel[0m[1;31m)[0m[31m for adverse event incidence was â‰¤ [0m[1;31m0.10[0m[31m. â€¡ Denominators for events in [0m
[31mgender-specific systems are: n = [0m[1;31m240[0m[31m [0m[1;31m([0m[31mclonazepam[0m[1;31m)[0m[31m, [0m[1;31m102[0m[31m [0m[1;31m([0m[31mplacebo[0m[1;31m)[0m[31m for male, and [0m[1;31m334[0m[31m [0m[1;31m([0m[31mclonazepam[0m[1;31m)[0m[31m, [0m[1;31m192[0m[31m [0m[1;31m([0m[31mplacebo[0m[1;31m)[0m[31m for female. CLONAZEPAM: adverse_reactions: Clonazepam Maximum Daily Dose Adverse Event by[0m
[31mBody System < [0m[1;31m1[0m[31m mg n = [0m[1;31m96[0m[31m % [0m[1;31m1[0m[31m - < [0m[1;31m2[0m[31m mg n = [0m[1;31m129[0m[31m % [0m[1;31m2[0m[31m - < [0m[1;31m3[0m[31m mg n = [0m[1;31m113[0m[31m % â‰¥ [0m[1;31m3[0m[31m mg n = [0m[1;31m235[0m[31m % All Clonazepam Tablets Groups N = [0m[1;31m574[0m[31m % Placebo N = [0m[1;31m294[0m[31m % Central & Peripheral Nervous System Somnolence â€  [0m[1;31m26[0m[31m [0m[1;31m35[0m[31m [0m
[1;31m50[0m[31m [0m[1;31m36[0m[31m [0m[1;31m37[0m[31m [0m[1;31m10[0m[31m Dizziness [0m[1;31m5[0m[31m [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m8[0m[31m [0m[1;31m8[0m[31m [0m[1;31m4[0m[31m Coordination Abnormal â€  [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m7[0m[31m [0m[1;31m9[0m[31m [0m[1;31m6[0m[31m [0m[1;31m0[0m[31m Ataxia â€  [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m8[0m[31m [0m[1;31m8[0m[31m [0m[1;31m5[0m[31m [0m[1;31m0[0m[31m Dysarthria â€  [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m Psychiatric Depression [0m[1;31m7[0m[31m [0m[1;31m6[0m[31m [0m[1;31m8[0m[31m [0m[1;31m8[0m[31m [0m[1;31m7[0m[31m [0m[1;31m1[0m[31m Memory Disturbance [0m[1;31m2[0m[31m [0m[1;31m5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m5[0m[31m [0m[1;31m4[0m[31m [0m[1;31m2[0m[31m Nervous [0m
[31mCLONAZEPAM: adverse_reactions: ness [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Intellectual Ability Reduced [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m Emotional Lability [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Libido Decreased [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Confusion [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Respiratory System Upper [0m
[31mRespiratory Tract Infection â€  [0m[1;31m10[0m[31m [0m[1;31m10[0m[31m [0m[1;31m7[0m[31m [0m[1;31m6[0m[31m [0m[1;31m8[0m[31m [0m[1;31m4[0m[31m Sinusitis [0m[1;31m4[0m[31m [0m[1;31m2[0m[31m [0m[1;31m8[0m[31m [0m[1;31m4[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m Rhinitis [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m Coughing [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m Pharyngitis [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m Bronchitis [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Gastrointestinal System Constipation â€  [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m5[0m[31m [0m
[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m Appetite Decreased [0m[1;31m1[0m[31m CLONAZEPAM: adverse_reactions: [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Abdominal Pain â€  [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Body as a Whole Fatigue [0m[1;31m9[0m[31m [0m[1;31m6[0m[31m [0m[1;31m7[0m[31m [0m[1;31m7[0m[31m [0m[1;31m7[0m[31m [0m[1;31m4[0m[31m Allergic Reaction [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m Musculoskeletal Myalgia [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m
[31mResistance Mechanism Disorders Influenza [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m [0m[1;31m5[0m[31m [0m[1;31m5[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m Urinary System Micturition Frequency [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Urinary Tract Infection â€  [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Vision Disorders Blurred Vision [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Reproductive [0m
[31mDisorders â€¡ Female Dysmenorrhea [0m[1;31m0[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Colpitis [0m[1;31m4[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m Male Ejaculation Delayed CLONAZEPAM: adverse_reactions: [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Impotence [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Commonly Observed Adverse Events: Table [0m[1;31m4[0m[31m. [0m
[31mIncidence of Most Commonly Observed Adverse Events * in Acute Therapy in Pool of [0m[1;31m6[0m[31m- to [0m[1;31m9[0m[31m-Week Trials * Treatment-emergent events for which the incidence in the clonazepam patients was â‰¥ [0m[1;31m5[0m[31m% and at [0m
[31mleast twice that in the placebo patients.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: warnings: Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages, and [0m
[31mthose who have had longer durations of use. Acute Withdrawal Reactions The continued use of benzodiazepines, including clonazepam tablets, may lead to clinically significant physical dependence. [0m
[31mAbrupt discontinuation or rapid dosage reduction of clonazepam tablets after continued use, or administration of flumazenil [0m[1;31m([0m[31ma benzodiazepine antagonist[0m[1;31m)[0m[31m may precipitate acute withdrawal reactions, [0m
[31mwhich can be life-threatening [0m[1;31m([0m[31me.g., seizures[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee DRUG ABUSE AND DEPENDENCE: Dependence [0m[1;31m)[0m[31m . Protracted Withdrawal Syndrome In some cases, benzodiazepine users have developed a protracted withdrawal [0m
[31msyndrome with withdrawal symptoms lasting weeks to more than [0m[1;31m12[0m[31m months [0m[1;31m([0m[31msee DRUG ABUSE AND DEPENDENCE: Dependence [0m[1;31m)[0m[31m. CLONAZEPAM: warnings: Interference with Cognitive and Motor Performance: Since [0m
[31mclonazepam tablets produce CNS depression, patients receiving this drug should be cautioned against engaging in hazardous occupations requiring mental alertness, such as operating machinery or driving[0m
[31ma motor vehicle. They should also be warned about the concomitant use of alcohol or other CNS-depressant drugs during clonazepam tablets therapy [0m[1;31m([0m[31msee PRECAUTIONS: Drug Interactions and PRECAUTIONS: [0m
[31mInformation for Patients [0m[1;31m)[0m[31m. Suicidal Behavior and Ideation: Antiepileptic drugs [0m[1;31m([0m[31mAEDs[0m[1;31m)[0m[31m, including clonazepam tablets, increase the risk of suicidal thoughts or behavior in patients taking these drugs [0m
[31mfor any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood[0m
[31mor behavior. CLONAZEPAM: warnings: Pooled analyses of [0m[1;31m199[0m[31m placebo-controlled clinical trials [0m[1;31m([0m[31mmono- and adjunctive therapy[0m[1;31m)[0m[31m of [0m[1;31m11[0m[31m different AEDs showed that patients randomized to one of the AEDs had [0m
[31mapproximately twice the risk [0m[1;31m([0m[31madjusted Relative Risk [0m[1;31m1.8[0m[31m, [0m[1;31m95[0m[31m% CI:[0m[1;31m1.2[0m[31m, [0m[1;31m2.7[0m[1;31m)[0m[31m of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment [0m
[31mduration of [0m[1;31m12[0m[31m weeks, the estimated incidence rate of suicidal behavior or ideation among [0m[1;31m27[0m[31m,[0m[1;31m863[0m[31m AED-treated patients was [0m[1;31m0.43[0m[31m% compared to [0m[1;31m0.24[0m[31m% among [0m[1;31m16[0m[31m,[0m[1;31m029[0m[31m placebo-treated patients, representing an[0m
[31mincrease of approximately one case of suicidal thinking or behavior for every [0m[1;31m530[0m[31m patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated [0m
[31mpatients, but the number is too small to allow any conclusion about drug effect on suicide. CLONAZEPAM: warnings: The increased risk of suicidal thoughts or behavior with AEDs was observed as early as[0m
[31mone week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond [0m[1;31m24[0m[31m weeks, the risk of suicidal[0m
[31mthoughts or behavior beyond [0m[1;31m24[0m[31m weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs[0m
[31mof varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age [0m[1;31m([0m[1;31m5[0m[31m to [0m[1;31m100[0m[31m years[0m[1;31m)[0m[31m in the[0m
[31mclinical trials analyzed. Table [0m[1;31m1[0m[31m shows absolute and relative risk by indication for all evaluated AEDs. Table [0m[1;31m1[0m[31m. CLONAZEPAM: warnings: Risk by Indication for Antiepileptic Drugs in the Pooled [0m
[31mAnalysis Indication Placebo Drug Patients Relative Risk: Risk Difference: Patients with with Events Per Incidence of Additional Drug Events Per [0m[1;31m1000[0m[31m Patients Events in Drug Patients with [0m[1;31m1000[0m[31m Patients[0m
[31mPatients/Incidence Events per [0m[1;31m1000[0m[31m in Placebo Patients Patients Epilepsy [0m[1;31m1.0[0m[31m [0m[1;31m3.4[0m[31m [0m[1;31m3.5[0m[31m [0m[1;31m2.4[0m[31m Psychiatric [0m[1;31m5.7[0m[31m [0m[1;31m8.5[0m[31m [0m[1;31m1.5[0m[31m [0m[1;31m2.9[0m[31m Other [0m[1;31m1.0[0m[31m [0m[1;31m1.8[0m[31m [0m[1;31m1.9[0m[31m [0m[1;31m0.9[0m[31m Total [0m[1;31m2.4[0m[31m [0m[1;31m4.3[0m[31m [0m[1;31m1.8[0m[31m [0m[1;31m1.9[0m[31m The relative risk for suicidal thoughts[0m
[31mor behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric [0m
[31mindications. CLONAZEPAM: warnings: Anyone considering prescribing clonazepam tablets or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. [0m
[31mEpilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and with an increased risk of suicidal thoughts and behavior. Should suicidal [0m
[31mthoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. Patients, [0m
[31mtheir caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the [0m
[31msigns and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported [0m
[31mimmediately to healthcare providers. CLONAZEPAM: warnings: Neonatal Sedation and Withdrawal Syndrome: Use of clonazepam tablets late in pregnancy can result in sedation [0m[1;31m([0m[31mrespiratory depression, [0m
[31mlethargy, hypotonia[0m[1;31m)[0m[31m and/or withdrawal symptoms [0m[1;31m([0m[31mhyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties[0m[1;31m)[0m[31m in the neonate [0m[1;31m([0m[31msee PRECAUTIONS: Pregnancy [0m[1;31m)[0m[31m. [0m
[31mMonitor neonates exposed to clonazepam tablets during pregnancy or labor for signs of sedation and monitor neonates exposed to clonazepam tablets during pregnancy for signs of withdrawal; manage these[0m
[31mneonates accordingly.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The available information from the CLONAZEPAM label does not provide a direct answer regarding the impact of clonazepam on the risk of hip fracture. However, it does list [0m[32m"fracture traumatic"[0m[32m [0m
[32mas one of the infrequent adverse events reported by patients treated with clonazepam tablets during clinical trials. Infrequent adverse events are defined as occurring in [0m[1;32m1[0m[32m/[0m[1;32m100[0m[32m to [0m[1;32m1[0m[32m/[0m[1;32m1000[0m[32m patients. [0m
[32mThis does not specifically address the risk of hip fractures, nor does it establish a causal relationship between clonazepam use and fractures.[0m

[32mSOURCE: CLONAZEPAM label[0m
[32mEXTRACT_START_END: Musculoskeletal System Disorders: back pain, fracture traumatic,[0m[32m...[0m
*[1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The available information from the CLONAZEPAM label does not [0m
[34mprovide a direct answer regarding the impact of clonazepam on the risk of hip fracture. However, it does list [0m[34m"fracture traumatic"[0m[34m as one of the infrequent adverse events reported by patients treated [0m
[34mwith clonazepam tablets during clinical trials. Infrequent adverse events are defined as occurring in [0m[1;34m1[0m[34m/[0m[1;34m100[0m[34m to [0m[1;34m1[0m[34m/[0m[1;34m1000[0m[34m patients. This does not specifically address the risk of hip fractures, nor does [0m
[34mit establish a causal relationship between clonazepam use and fractures.[0m

[34mSOURCE: CLONAZEPAM label[0m
[34mEXTRACT_START_END: Musculoskeletal System Disorders: back pain, fracture traumatic,[0m[34m...[0m
 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does CLONAZEPAM increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether CLONAZEPAM increases or decreases the risk of hip fracture."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the CLONAZEPAM label does not provide a direct answer regarding the impact of clonazepam on the risk of hip fracture."[0m[32m,[0m
[32m      [0m[32m"The label does list \"fracture traumatic\" as an infrequent adverse event reported by patients treated with clonazepam tablets during clinical trials, which occurs in 1/100 to 1/1000 patients. [0m
[32mHowever, this does not specifically address the risk of hip fractures, nor does it establish a causal relationship between clonazepam use and fractures."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does CLONAZEPAM increase or decrease the risk of hip fracture?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether CLONAZEPAM increases or decreases the risk of hip fracture."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the CLONAZEPAM label does not provide a direct answer regarding the impact of clonazepam on the risk of hip fracture."[0m[34m,[0m
[34m      [0m[34m"The label does list \"fracture traumatic\" as an infrequent adverse event reported by patients treated with clonazepam tablets during clinical trials, which occurs in 1/100 to 1/1000 patients. [0m
[34mHowever, this does not specifically address the risk of hip fractures, nor does it establish a causal relationship between clonazepam use and fractures."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does CLONAZEPAM increase or decrease the risk of hip fracture?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether CLONAZEPAM increases or decreases the risk of hip fracture.[0m
[1;31m2[0m[31m. FDAHandler responded that the CLONAZEPAM label does not provide a direct answer regarding the impact of clonazepam on the risk of hip fracture.[0m
[1;31m3[0m[31m. The label does list [0m[31m"fracture traumatic"[0m[31m as an infrequent adverse event reported by patients treated with clonazepam tablets during clinical trials, which occurs in [0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m to [0m[1;31m1[0m[31m/[0m[1;31m1000[0m[31m patients. [0m
[31mHowever, this does not specifically address the risk of hip fractures, nor does it establish a causal relationship between clonazepam use and fractures.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hip fracture-CLONAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label for CLONAZEPAM does not provide a direct answer regarding the impact of clonazepam on the risk of hip fracture. It does list [0m[32m"fracture traumatic"[0m[32m as an infrequent adverse event reported [0m
[32mby patients treated with clonazepam tablets during clinical trials, which occurs in [0m[1;32m1[0m[32m/[0m[1;32m100[0m[32m to [0m[1;32m1[0m[32m/[0m[1;32m1000[0m[32m patients. However, this information does not specifically address the risk of hip fractures, nor [0m
[32mdoes it establish a causal relationship between clonazepam use and fractures.[0m
